Cayuga Biotech Announces that PolyP-SNP Complex Data Demonstrate 12x Faster Coagulation in Life-Threatening Hemorrhage Which Results in Two Million Deaths Globally Each Year
June 26 2024 - 12:32AM
Business Wire
-- Novel therapy also shows low potential
for off-target effects --
Cayuga Biotech, a company that develops drugs that harness the
body’s innate ability to heal and stop bleeding, today presented
preclinical data on its first generation, first-in-class,
polyphosphate (polyP)-based therapy designed to address
life-threatening hemorrhage. The results demonstrated that the
polyP-SNP (silica nanoparticle) complex, in both standard and
lethal triad conditions in vitro and ex vivo, generated thrombin 12
times faster than control, resulting in faster clotting with low
potential for off-target thromboembolism. These data were presented
in both oral and poster presentations at the Annual Meeting of the
International Society for Thrombosis and Haemostasis in Bangkok,
Thailand.
“The potential of exogenous polyP to stop noncompressible
hemorrhage has previously been limited by its inability to be
delivered systemically,” said study co-author James Morrissey, PhD,
Professor of Biological Chemistry and Internal Medicine, Cardiology
at the University of Michigan, who also led the characterization of
polyphosphate’s hemostatic properties in humans. “These data are
exciting because this novel polyP-SNP complex has overcome these
limitations while demonstrating superior clotting in both standard
and simulated ‘lethal triad’ (hemodilution, hypothermia and
acidosis) conditions that compromise the body’s ability to stop
bleeding.”
Data presented in the ISTH “New strategies for reversal and
prevention of bleeding” session demonstrated faster clotting in
vitro and ex vivo and acceleration of thrombin generation, which is
the critical factor that determines the ability to clot quickly and
effectively. As an injected drug that is inert in healthy tissue,
the polyP-SNP complex travels via the bloodstream to any site of
bleeding and acts to accelerate the clotting response without
driving excess clotting. The activity of polyP-SNP complex is
independent of FXII activation, which suggests a low potential for
causing clotting in healthy tissue, a problem that has limited
development for other injectable drugs to treat hemorrhage.
The study abstracts are available on the ISTH website at
https://www.isth2024.org.
“A synthetic short-chain polyphosphate (polyP) complexed with
silica nanoparticle (SNP), has pro-hemostatic activities as
assessed by in vitro and ex vivo studies” (OC 43.2)
“A synthetic short-chain polyphosphate (polyP) complexed with
silica nanoparticle (SNP), corrects coagulopathy under hemodilute,
hypothermic, or acidotic conditions” (PB1047)
About Hemorrhage
Nearly 2 million people globally per year die of hemorrhage, the
majority of which is preventable. The top causes of preventable
death by hemorrhage are non-compressible hemorrhage sites (such as
internal bleeding and from penetrating injury) and delays in
hemostatic control neither of which are adequately addressed by
today’s current care model. Due to the nature of non-compressible
hemorrhage sites, the complexity of clinical intervention is time
consuming and delays in treatment often lead to patient death.
About Cayuga Biotech, Inc.
Cayuga is developing novel biomimetic therapies leveraging
inorganic polyphosphate, a polymer that modulates the healing
response. The company has an optimized polyP-SNP complex in late
preclinical development for the treatment of acute major
hemorrhage, a discovery-stage novel composition for the treatment
of inherited bleeding disorders, as well as a portfolio of
early-stage programs focused across the healing continuum. To learn
more, please visit www.CayugaBiotech.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240625026996/en/
Andrea Ashford-Hicks Media@cayugabiotech.com